Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 16,310 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 16,310 shares of the stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $0.65, for a total transaction of $10,601.50. Following the transaction, the director directly owned 2,694,912 shares in the company, valued at $1,751,692.80. The trade was a 0.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Luke Evnin also recently made the following trade(s):

• On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total value of $66,249.66.
• On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $22,448.16.
• On Tuesday, December 23rd, Luke Evnin sold 71,428 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $44,999.64.
• On Monday, December 22nd, Luke Evnin sold 59,307 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total value of $40,921.83.
• On Wednesday, December 17th, Luke Evnin sold 9,983 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total value of $11,380.62.
• On Tuesday, December 16th, Luke Evnin sold 14,548 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.05, for a total transaction of $15,275.40.
• On Monday, December 15th, Luke Evnin sold 23,640 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.07, for a total transaction of $25,294.80.
• On Friday, December 12th, Luke Evnin sold 17,858 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.08, for a total transaction of $19,286.64.
• On Thursday, December 11th, Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.07, for a total transaction of $29,969.63.
• On Wednesday, December 10th, Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.06, for a total transaction of $39,330.24.

Werewolf Therapeutics Stock Performance

NASDAQ HOWL traded down $0.03 during trading hours on Monday, reaching $0.62. The company’s stock had a trading volume of 1,846,563 shares, compared to its average volume of 537,572. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. The business has a 50-day simple moving average of $1.08 and a 200 day simple moving average of $1.29. Werewolf Therapeutics, Inc. has a 52 week low of $0.56 and a 52 week high of $2.38. The stock has a market cap of $30.15 million, a PE ratio of -0.38 and a beta of 0.74.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. Equities research analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HOWL has been the subject of several recent research reports. Wedbush lowered shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price target for the company. in a research report on Friday, December 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Citizens Jmp lowered shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, December 19th. Citigroup cut Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, December 19th. Finally, Bank of America decreased their price objective on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Three equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Werewolf Therapeutics has an average rating of “Hold” and a consensus price target of $3.75.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quadrature Capital Ltd acquired a new position in shares of Werewolf Therapeutics during the second quarter valued at approximately $28,000. Qube Research & Technologies Ltd bought a new position in Werewolf Therapeutics during the 2nd quarter valued at $48,000. Nuveen LLC bought a new position in Werewolf Therapeutics during the 1st quarter valued at $71,000. AQR Capital Management LLC bought a new stake in shares of Werewolf Therapeutics in the 1st quarter worth $79,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth $92,000. 64.84% of the stock is currently owned by institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.